Get the Stockscreener App
5.0023
2.87%
-0.1477
Bolt Biotherapeutics Inc stock is traded at $5.0023, with a volume of 12,865.
It is down -2.87% in the last 24 hours and down -9.54% over the past month.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
See More
Previous Close:
$5.15
Open:
$5.13
24h Volume:
12,865
Relative Volume:
0.47
Market Cap:
$9.59M
Revenue:
$7.88M
Net Income/Loss:
$-69.20M
P/E Ratio:
-2.7335
EPS:
-1.83
Net Cash Flow:
$-69.73M
1W Performance:
-11.21%
1M Performance:
-9.54%
6M Performance:
-49.09%
1Y Performance:
-63.96%
1-Day Range:
$4.98
$5.17
1-Week Range:
$4.98
$5.9771
52-Week Range:
$4.98
$14.36
Bolt Biotherapeutics Inc Stock (BOLT) Company Profile
Name
Bolt Biotherapeutics Inc
Sector
Industry
Phone
650-665-9295
Address
900 CHESAPEAKE DRIVE, REDWOOD CITY
Compare BOLT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BOLT
Bolt Biotherapeutics Inc
|
5.0023 | 9.87M | 7.88M | -69.20M | -69.73M | -1.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.32 | 100.71B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.58 | 61.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.26 | 58.84B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
665.24 | 40.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
325.03 | 38.20B | 3.81B | -644.79M | -669.77M | -6.24 |
Bolt Biotherapeutics Inc Stock (BOLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-02-21 | Initiated | Guggenheim | Buy |
| Mar-02-21 | Initiated | Morgan Stanley | Overweight |
| Mar-02-21 | Initiated | SVB Leerink | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
Bolt Biotherapeutics Inc Stock (BOLT) Latest News
Evaluating Bolt Biotherapeutics Inc. with trendline analysisOil Prices & AI Optimized Trading Strategy Guides - Newser
Trend analysis for Bolt Biotherapeutics Inc. this weekPortfolio Growth Summary & High Conviction Buy Zone Picks - Newser
What MACD signals say about Bolt Biotherapeutics Inc.Bull Run & Weekly High Momentum Picks - Newser
Will breakout in Bolt Biotherapeutics Inc. lead to full recoveryMarket Performance Report & Verified Momentum Watchlists - Newser
Best data tools to analyze Bolt Biotherapeutics Inc. stock2025 Major Catalysts & Accurate Technical Buy Alerts - Newser
Using economic indicators to assess Bolt Biotherapeutics Inc. potential2025 Top Gainers & Daily Volume Surge Signals - Newser
Will Bolt Biotherapeutics Inc. bounce back from current supportWeekly Risk Summary & Weekly Momentum Picks - Newser
Long term hold vs stop loss in Bolt Biotherapeutics Inc.Gap Up & Stepwise Entry and Exit Trade Signals - Newser
Bolt Biotherapeutics (NASDAQ:BOLT) Stock Price Expected to Rise, Lake Street Capital Analyst Says - Defense World
Is Bolt Biotherapeutics Inc. meeting your algorithmic filter criteriaQuarterly Portfolio Report & Verified High Yield Trade Plans - Newser
Short interest data insights for Bolt Biotherapeutics Inc.July 2025 Recap & Expert Curated Trade Ideas - Newser
Multi asset correlation models including Bolt Biotherapeutics Inc.July 2025 Catalysts & Weekly High Momentum Picks - Newser
Can technical indicators confirm Bolt Biotherapeutics Inc.’s reversal2025 Breakouts & Breakdowns & Community Shared Stock Ideas - Newser
Can momentum traders help lift Bolt Biotherapeutics Inc.July 2025 Highlights & Free Verified High Yield Trade Plans - Newser
Bolt Biotherapeutics 2025 Q2 Earnings 59.6% Reduction in Net Loss - AInvest
Intraday pattern recognizer results for Bolt Biotherapeutics Inc.2025 Buyback Activity & Weekly Stock Breakout Alerts - Newser
Heatmap analysis for Bolt Biotherapeutics Inc. and competitors2025 Price Action Summary & High Return Trade Guides - Newser
Bolt Biotherapeutics Inc.: Q2 Earnings Snapshot - Norwalk Hour
Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Tops Revenue Estimates - ca.finance.yahoo.com
Bolt Biotherapeutics: A Case Study in Operational Efficiency and Revenue Upside in Early-Stage Biotech - AInvest
Bolt Biotherapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Bolt Bio's New Cancer Drug Enters Clinical Trials as Company Extends Cash Runway Through 2026 - Stock Titan
Key metrics from Bolt Biotherapeutics Inc.’s quarterly data2025 Performance Recap & Entry Point Strategy Guides - Newser
Will earnings trigger a reversal in Bolt Biotherapeutics Inc.M&A Rumor & Long-Term Safe Return Strategies - Newser
Is Bolt Biotherapeutics Inc. forming a bottoming basePortfolio Value Report & Risk Controlled Swing Alerts - Newser
Predicting Bolt Biotherapeutics Inc. trend using moving averagesFree Short Term Buy List With Stop Protection - Newser
Why Bolt Biotherapeutics Inc. stock attracts strong analyst attentionVolume Based Swing Signal Prediction Map - Newser
Bolt Biotherapeutics (BOLT) Expected to Announce Earnings on Tuesday - Defense World
Bolt Biotherapeutics BOLT 2025Q2 Earnings Preview Upside Ahead on Promising Clinical Trials - AInvest
Bolt Biotherapeutics Inc Stock (BOLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):